DNMT inhibitors work by blocking the addition of methyl groups to DNA, thereby reversing aberrant methylation patterns. This can restore the expression of tumor suppressor genes and other important regulatory genes that have been epigenetically silenced in cancer. The two most widely studied DNMT inhibitors are azacitidine and decitabine. These drugs incorporate into DNA and trap DNA methyltransferases, leading to their degradation.
